고려제약

014570KOSDAQ의약품 제조업

60.3 / 100

Reference Date: 2026-07-24

Financial Score28.0 / 40

News Sentiment16.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Rose 6.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Pharmaceutical Co., Ltd. is a leading South Korean manufacturer of over-the-counter and specialty pharmaceuticals, renowned for its cold remedy 'Haben' and treatments for CNS diseases such as epilepsy and Parkinson's. The company's flagship products include CNS medications, which are sold through pharmacies, hospitals, and international exports, while also focusing on R&D for new drugs and health functional foods.

Number of Employees

238people

Average Salary

55.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.74Industry Average 11.236.5Point

Lower than industry avg (good)

PBR

0.45Industry Average 0.815.5Point

Lower than industry avg (good)

ROE

8.08Industry Average 4.017.0Point

2.0x industry avg (excellent)

Debt Ratio

3.56Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼36.8% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.0% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65

Negative
고려제약, 이천세무서로부터 추징금 52억원 부과
고려제약이 세무조사 결과로 인해 대규모 추징금을 부과받아 재무상태에 부정적 영향을 받음.

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 3,400Won52-week high 4,71052-week low 3,155

1-month return4.0Point

1m +6.25% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral벌금등의부과2026-07-10